Subjective cognitive complaints may be the earliest detectable stages of preclinical dementia.
Dementia—it’s one of the most dreaded diseases of our time. About 5.8 million people are currently living with Alzheimer’s disease, the most common form of dementia. And that number is expected to skyrocket to 14 million by 2050.
Screening for Alzheimer’s disease and related dementias in primary care settings did not result in any harm as measured by patient-reported anxiety and depressive symptoms, according to findings of a randomized controlled trial published in Journal of the American Geriatrics Society.
We are experiencing an absolute epidemic of Lyme disease in the United States. Making things even worse is that many physicians don’t understand or deny that Lyme is so serious. It’s a tragedy.
Doctors may be not be diagnosing women as early as men with brain problems associated with early signs of dementia because of how well women typically perform on simple memory tests.
Just about every day, there’s a new headline about this or that factor possibly contributing to Alzheimer’s Disease. Is it genetics, lifestyle, diet, chemical exposures, something else?
A test that measures beta amyloid protein in the blood is more accurate than a brain scan and may indicate trouble years earlier.
Recently, the Alzheimer’s Drug Discovery Foundation gave researchers a $3.5 million award for promising early detection Alzheimer’s tests.
Fear of Alzheimer’s disease and other dementias has become so deeply ingrained in our society that they believe — wrongly — that a dementia diagnosis might as well be a death sentence.
Nobel prizewinner Koichi Tanaka says the predictive blood test for Alzheimer’s disease he and colleagues spent almost a decade developing is a double-edged sword.